OR WAIT null SECS
July 03, 2025
Article
Our recap of the first half of 2025 highlights 5 regulatory updates, 5 trial announcements, and 3 top perspectives in hematology.
July 02, 2025
A relatively quiet quarter for hematology, punctuated by both successes and failures in clinical trials and a handful of Orphan Drug and Fast Track designations.
July 01, 2025
The FDA distributed several designations and many trials successfully met their endpoints during an eventful June for hematology.
June 21, 2025
Hereditary hemorrhagic telangiectasia has no approved treatments; this designation, in addition to the European Medicines Agency granting a positive opinion, positions DIAG723 to be the first.
June 20, 2025
Investigators also noted the risk of Hb overshoot in patients switching from ESA to roxadustat, emphasizing the importance of monitoring Hb levels before and after treatment.
June 05, 2025
Investigators compared the medications across various patient cohorts with different causes of anemia, finding evidence almost uniformly in favor of FCM.
June 04, 2025
A recent analysis reveals no significant difference between restrictive and liberal transfusion strategies on quality of life in patients with myocardial infarction and anemia.
June 03, 2025
A relatively quiet month for hematology, marked by brief ups and downs for trials and new research on anemia and sickle cell disease.
May 31, 2025
A recent study has indicated that FCH results in better tolerability and medication compliance due to lowered risk of adverse gastrointestinal effects.
May 30, 2025
Iron deficient diets can lead to anemia and various other health complications in adulthood.
